scholarly journals Assessment of the risk of incident heart failure in osteoporosis patients: a systematic review and meta-analysis of eligible cohort studies

2020 ◽  
Author(s):  
Zhenjie Gu ◽  
Yang Yuanyuan ◽  
Zhang Lingyu ◽  
Chen Cong
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Cohort Studies ◽  
Meta Analysis ◽  
Incident Heart Failure

scholarly journals Influence of Smoking Status on Risk of Incident Heart Failure: A Systematic Review and Meta-Analysis of Prospective Cohort Studies

2019 ◽  
Vol 16 (15) ◽  
pp. 2697 ◽  
Author(s):  
Hyeonju Lee ◽  
Youn-Jung Son
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Cohort Studies ◽  
Prospective Cohort ◽  
Smoking Status ◽  
Meta Analysis ◽  
Prospective Cohort Studies ◽  
Former Smokers ◽  
Incident Heart Failure ◽  
Never Smokers

Smoking is a well-known risk factor for atherosclerotic cardiovascular disease. However, there are insufficient data regarding the predictive influence of smoking status on the risk of incident heart failure (HF). This study involved a systematic review and meta-analysis of prospective cohort studies to identify the association of smoking status with incident risk of HF. Peer-reviewed articles published in PubMed, Embase, Web of Science, Cochrane, and CINAHL up to May 2019 were identified. Seven studies, based on 42,759 participants and 4826 HF cases, were included. Pooled hazard ratios (HRs) and their 95% confidence intervals (CI) were estimated using the fixed effects model. Subgroup analyses were conducted to define possible sources of heterogeneity. Current smokers aged 18 years and over had a greater risk of HF incidence compared with non-smokers (never or former smokers) (HR = 1.609, 95% CI, 1.470–1.761). Additionally, former smokers had a greater risk of HF incidence compared with never smokers (HR = 1.209, 95% CI, 1.084–1.348). The present study highlighted that never smokers have more obvious cardiovascular benefits than current or former smokers. Therefore, health professionals should support cessation at the earliest among current smokers and encourage young people and non-smokers not to start smoking.

scholarly journals Clinical prediction of incident heart failure risk: a systematic review and meta-analysis

Open Heart ◽  
2015 ◽  
Vol 2 (1) ◽  
pp. e000222 ◽  
Author(s):  
Hong Yang ◽  
Kazuaki Negishi ◽  
Petr Otahal ◽  
Thomas H Marwick
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Meta Analysis ◽  
Clinical Prediction ◽  
Failure Risk ◽  
Incident Heart Failure

scholarly journals Resting Heart Rate and Risk of Incident Heart Failure: Three Prospective Cohort Studies and a Systematic Meta‐Analysis

2015 ◽  
Vol 4 (1) ◽  
Author(s):  
Hassan Khan ◽  
Setor Kunutsor ◽  
Andreas P. Kalogeropoulos ◽  
Vasiliki V. Georgiopoulou ◽  
Anne B. Newman ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Cohort Studies ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Resting Heart Rate ◽  
Prospective Cohort Studies ◽  
Incident Heart Failure

scholarly journals Intravenous Iron Decreases Rehospitalizations but Does not Change mortality in Patients Admitted with Acute Heart Failure and Iron Deficiency: A Systematic review and Meta-analysis

2021 ◽  
Author(s):  
Nischit Baral ◽  
Nabin Raj Karki ◽  
Imran Akram ◽  
Ashiya Khan ◽  
Govinda Adhikari ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Iron Deficiency ◽  
Cohort Studies ◽  
Meta Analysis ◽  
Placebo Control ◽  
Hospitalization Rates ◽  
Iv Iron ◽  
Overall Mortality

Introduction: The role of intravenous (IV) iron in chronic heart failure has been well studied, however, its role in acute heart failure (AHF) is less well-known. Including the recent AFFIRM-HF trial, we performed a systematic review and meta-analysis to highlight the role of IV iron in AHF with iron deficiency. Hypothesis: We hypothesized that IV iron does not change mortality or heart failure re-hospitalization rates in patients with AHF with iron deficiency. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and cohort studies published from inception till June 30, 2021. We searched PubMed, MEDLINE, EMBASE (embase.com), and Cochrane database including only RCTs and Cohort studies. We also included one prospective and one retrospective Cohort studies and two RCTs in our meta-analysis. Eligible studies included adults with AHF, left ventricular ejection fraction less than 40%-50%, and able to receive IV iron therapy. Outcomes included re-hospitalization rates and overall mortality from 30 days to 52 weeks post randomization (in one RCT). We used random-effects model calculating Risk Ratio (RR) with 95% confidence interval (95% CI) using Review Manger 5.4 software. I2statistics was used to assess heterogeneity. Results: There were total 1561 participants in both groups (IV iron and placebo/control) of four studies. The controls were comparable in both cohort studies and both the RCTs were well matched. Our results showed re-hospitalization in 278 of 833 (33.37%) patients in the IV iron/exposure group and 337 of 728 (0.46%) patients in the placebo/control group. The pooled result showed that the risk of re-hospitalization was comparable across both groups (RR 0.85, 95%CI 0.62-1.17; I2=45%, P=0.14). However, subgroup analysis, including RCTs only showed that IV iron decreases re-hospitalization rate by 28% compared to placebo (RR 0.72, 95% CI: 0.64, 0.82, I2=0%, P<0.00001) but did not improve mortality when compared to placebo (RR 0.97, 95% CI: 0.73, 1.30, I2 =0%). Conclusions: IV iron showed significant improvement in re-hospitalization rate for AHF hospitalizations in iron deficient patients but did not improve overall mortality. We need larger RCTs to further validate its effect on mortality.

scholarly journals Clinical effectiveness of therapy with continuous-flow left ventricular assist devices in nonischemic versus ischemic cardiomyopathy: a systematic review and meta-analysis

2021 ◽  
Vol 64 (1) ◽  
pp. E39-E47
Author(s):  
Christopher Wavell ◽  
Andrew Sokolowski ◽  
Michelle L. Klingel ◽  
Charles Yin ◽  
Dave Nagpal
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Cohort Studies ◽  
Ischemic Cardiomyopathy ◽  
Cardiac Transplantation ◽  
Meta Analysis ◽  
Left Ventricular ◽  
Ventricular Assist ◽  
Left Ventricular Assist

Background: Clinicians may be less inclined to consider long-term left ventricular assist device (LVAD) therapy in end-stage heart failure (ESHF) as a result of nonischemic cardiomyopathy (NICM) versus ischemic cardiomyopathy (ICM) owing to potentially greater right ventricular involvement in the former; however, it is unknown whether the cause of heart failure has a clinically meaningful effect on outcomes following LVAD implantation. In this systematic review, we aimed to determine whether ischemic versus nonischemic etiology has any impact on patient-relevant outcomes. Methods: We searched MEDLINE, Embase, PubMed and the Cochrane Library for studies published in English between Jan. 1, 2000, and Nov. 22, 2018, that examined survival and transplantation rates following LVAD implantation in patients with NICM or ICM. Randomized clinical trials, cohort studies, case–control studies, cross-sectional studies and case series with a sample size of at least 8 patients were eligible for inclusion. To be included in the meta-analysis, outcomes had to include at least death reported at 30 days or 1 year after LVAD implantation. Quality of included studies was assessed by 2 independent reviewers using the Newcastle–Ottawa Quality Assessment Scale for Cohort Studies. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) quality-assessment tool was used to assess outcomes (30-d survival, 1-yr survival and cardiac transplantation following LVAD therapy) across studies. Results: From a total of 2843 citations identified, 7 studies met all inclusion criteria. Studies were generally of good quality, but reporting of patient demographic characteristics, outcomes and complications was heterogeneous. We found no significant difference in 30-day or 1-year survival or in cardiac transplantation rates after device implantation between the NICM and ICM groups. Patients in the 2 groups had similar outcomes up to 1 year with LVAD therapy. Conclusion: Early outcomes of LVAD therapy do not appear to be affected by heart failure etiology. Ongoing investigation is required to determine the long-term outcomes of LVAD therapy in ICM and NICM. Systematic review registration: PROSPERO register, record ID 76483

Sign in / Sign up

Export Citation Format

Share Document